On August 5, 2025, Quest Diagnostics Inc. (NYSE: DGX), a prominent provider of diagnostic information services, announced the successful completion of its acquisition of select clinical testing assets from Fresenius Medical Care's wholly owned subsidiary, Spectra Laboratories. This strategic move underscores Quest's commitment to enhancing its clinical testing capabilities, particularly in the renal sector.

2. Enhancing Dialysis-Related Services

The acquisition allows Quest Diagnostics to expand its offerings to independent dialysis clinics that were previously served by Spectra Laboratories. This transition is expected to significantly enhance the quality and speed of dialysis-related testing services, benefiting both healthcare providers and patients.

In addition to the completed acquisition, Quest Diagnostics is on track to finalize the acquisition of specific dialysis-related water testing assets by the end of 2025. This will further strengthen Quest's capabilities in providing essential testing services vital for the management of chronic kidney disease (CKD).

3. Comprehensive Laboratory Services Agreement

As part of a previously announced laboratory services agreement, Quest will commence comprehensive dialysis-related laboratory services for Fresenius Medical Care-operated dialysis centers later this month. These centers serve approximately 200,000 patients annually, and the transition of services is anticipated to ramp up over the coming months, with a complete transition expected by early 2026.

This new arrangement is designed to leverage Quest's clinical expertise and innovation in chronic kidney disease services, ensuring that patients at dialysis clinics benefit from enhanced diagnostic support.

4. Addressing a Critical Health Concern

Chronic kidney disease is a significant health issue in the United States, affecting around 35.5 million people, or 14% of the population. Alarmingly, nearly 90% of adults with CKD are unaware of their condition. As CKD progresses to end-stage kidney disease (ESKD), patients often require dialysis or transplantation. Currently, more than 800,000 individuals in the U.S. rely on dialysis, which necessitates regular laboratory testing to manage their condition and ensure the safety of water used in the dialysis process.

Quest's expansion into dialysis-related services is expected to not only improve patient outcomes but also optimize its operational efficiencies. By conducting testing during lower-volume daytime hours, Quest aims to enhance its return on capital invested into its laboratory network, ultimately streamlining service delivery and reducing turnaround times for test results.

5. Conclusion

The completion of this acquisition marks a significant milestone for Quest Diagnostics, positioning the company to better serve the needs of dialysis patients and healthcare providers across the United States. With a focus on innovative diagnostic solutions and patient-centric services, Quest is poised to make a meaningful impact on the management of chronic kidney disease and the overall healthcare landscape.

As Quest Diagnostics continues to evolve and expand its service offerings, it remains dedicated to its mission of creating a healthier world, one life at a time. The integration of Fresenius Medical Care's clinical testing assets is a testament to this commitment, promising to enhance care delivery and improve health outcomes for millions of Americans.

Original press release